Caricamento...
Multi Targeted CAR-T Cell Therapies for B-Cell Malignancies
Chimeric antigen receptor (CAR) modified T cell therapy has revolutionized the treatment of relapsed and refractory hematological malignancies. Through targeting of the CD19 antigen on B cells durable remissions have been achieved in patients with B cell non-Hodgkin lymphoma and acute lymphoblastic...
Salvato in:
| Pubblicato in: | Front Oncol |
|---|---|
| Autori principali: | , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Frontiers Media S.A.
2019
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6423158/ https://ncbi.nlm.nih.gov/pubmed/30915277 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2019.00146 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|